2026-10-09 · 2026-10 / week-2
Alignment’s H3815 Star Cut Is Material, but the 23% After-Hours Gap Is Not a Bounded Short
Alignment’s H3815 Star Cut Is Material, but the 23% After-Hours Gap Is Not a Bounded Short
Summary: CMS’s 2027 ratings moved Alignment Healthcare’s California H3815 contract from 4.0 stars in the prior CMS table to 3.5, and the issuer says the contract serves about 75% of its members. Alignment also says the rating will not affect 2026-27 revenue, will affect 2028 quality-bonus payments, and provider risk-sharing should offset part of the impact. ALHC’s latest after-hours quote was $6.73. Against the $8.71 regular close, that is a calculated 22.73% decline; StockAnalysis displayed -22.79%, reflecting a slightly different quote baseline. The event is real; after that gap, the available evidence does not establish another 10% base decline or limit the squeeze/retracement path to 5%. Reject; no trade.
Publication time: Oct. 9, 2026, 08:41 Asia/Singapore (UTC+08:00).
Scope: U.S.-listed common stocks; short opportunities only. This is a no-trade research screen, not an order or personalized investment advice.
Market observation: The latest completed regular session is Oct. 8, 2026. StockAnalysis reports ALHC at $8.71 at the 4:00 p.m. EDT close, up 1.87%, with a regular-session range of $8.37-$8.77 and 9.53 million shares. At 7:59 p.m. EDT, the same vendor showed an after-hours mark of $6.73, down $1.98 or 22.73% by arithmetic from the displayed regular close. Its quote panel displayed a $1.99 change and -22.79%, a small baseline/rounding discrepancy. The after-hours mark is reference context only; it is not an executable entry or evidence of regular-session acceptance.
Decision: Reject / no trade. The after-hours repricing may prove durable, but the next regular session has not accepted it. The primary downside mechanism is prospective 2028 bonus-payment pressure, yet contract-level enrollment, incremental quality-bonus dollars, mitigation and litigation outcomes are not quantified. From the after-hours reference, the most-probable modeled case is not a 10% decline, and the adverse retracement stress exceeds 5%. Current locate, borrow, spread, depth, venue quality, volume quality and exit capacity are unverified.
Opportunity Ranking
| Rank | Candidate | Direction | Mispricing | Evidence Freshness | Catalyst Window | Positioning | 10/5 Status | Tradeability | Main Rejection Risk |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Alignment Healthcare (ALHC) | Short screen | H3815 fell from 4.0 to 3.5 stars and serves about 75% of members; the quality-bonus threshold is economically relevant, but the company says the change does not affect 2026-27 revenue, provider risk-sharing should offset part of the 2028 impact, and no dollar bridge is given. Six other eligible contracts rated 4.0+ | Oct. 8 CMS 2027 table, issuer 8-K and completed session; after-hours quote at 7:59 p.m. EDT | First regular-session acceptance Oct. 9; 2027 enrollment opens Oct. 15-Dec. 7; CMS says payment effects are in 2028 | Current short interest, locate, borrow, utilization and options positioning are not established in the sources reviewed | Reject: the after-hours price is not executable; no evidence-backed 10% base decline or 5% adverse bound | Nasdaq small-cap; after-hours gap and exit quality make a short especially fragile | Rating may be challenged or financially offset; the issuer says six other eligible contracts earned 4.0+ |
| 2 | CVS Health (CVS) | Short screen | CVS fell 3.04% after hours, but Aetna said 69% of MA members are in 2027 plans rated 4.0+; the cited 2.5-star low-performing contract had 9,358 October enrollees | Oct. 8 CMS data, Aetna issuer release and after-hours quote | 2027 enrollment season from Oct. 15-Dec. 7 | No current borrow or options data reviewed | Reject: a broad CVS price decline is not an issuer-specific 10% downside bridge from these rating facts | Deep NYSE listing, but the event price is after hours | Aetna’s 4+ star member share was strong and CMS flags only a comparatively small contract |
| 3 | Humana (HUM) | Short screen | H5216 improved from 3.5 to 4.0 stars in CMS’s year-to-year tables; HUM rose 12.88% after hours | Oct. 8 CMS data and after-hours quote | 2028 bonus-payment impact; first regular session Oct. 9 | Current borrow and positioning not reviewed | Reject: the new rating is positive, and the postmarket rise creates squeeze risk rather than a short catalyst | NYSE common; after-hours quote only | A move that retraces part of the surge is possible, but the star upgrade itself may support earnings and enrollment |
| 4 | SPY | Short control | No index-specific disagreement identified; use only as the broad-market control | Oct. 8 close | No company catalyst | Not underwritten | Control only | Liquid broad-market ETF; not a substitute for an issuer thesis | Sector-specific CMS news cannot establish an index short |
Selected opportunity: ALHC for information value, not as an attractive or executable short.
Why this one now: H3815’s new 3.5-star result crosses the 4.0-star quality-bonus threshold. The prior year’s 4.0 rating supported bonus eligibility, and the issuer said the contract had maintained at least four stars for nine consecutive years. This rating change is a material new event state. CMS says the 2027 ratings affect 2028 bonus payments, not a same-quarter cash loss.
What should surprise the reader: The bearish headline is incomplete. Alignment’s Oct. 8 release says six of its seven other eligible contracts scored 4.0 stars or more, including three at 4.5. It also says H3815 is 3.5 and says it intends administrative remedies and litigation. The large after-hours decline is a market observation; it does not tell us how much H3815 contributes to 2028 profit or whether the gap will hold in regular trading.
Why This Can Move More Than 5% Soon
The star threshold is discontinuous: a 3.5 rating and a 4.0 rating do not receive the same bonus treatment. In its Oct. 8 SEC filing, Alignment says H3815 serves approximately 75% of current health-plan membership; the underlying member count is not stated there. The company also says the rating will not affect fiscal 2026 or 2027 revenue, expects an effect on 2028 quality-bonus payments, and expects provider risk-sharing to offset a portion. The specific 2028 dollar impact remains unknown.
The observable catalyst path is short but two-sided. First, the Oct. 9 regular session will show whether buyers accept the overnight repricing. Then, beginning Oct. 15, beneficiaries can compare 2027 plans during open enrollment. The CMS payment consequence is in 2028, and litigation or administrative review could alter the result. The stock can move more than 5% in either direction, but that does not make a post-gap short asymmetric.
10/5 Asymmetry Gate
The event reference is $6.73, the latest StockAnalysis after-hours mark at 7:59 p.m. EDT on Oct. 8. The last completed regular close before the announcement was $8.71. The model horizon is one month, through Nov. 6, 2026. Because there is no supportable intrinsic-value bridge from the CMS rating to company earnings, the levels below are explicitly price-path stresses, not fair value or forecasts:
| Test | Reference-only result | Evidence limit |
|---|---|---|
| Highest-probability base case | $7.37, +9.5% underlying from $6.73 | Pre-event 52-week low; a retest level, not a predicted floor |
| Favorable top stress | $5.20, -22.7% underlying from $6.73 | Applies the same percentage decline as the observed $8.71-to-$6.73 after-hours gap a second time; mechanical stress, not valuation |
| Adverse bottom stress | $10.37, +54.1% underlying from $6.73 | Retest of the Sep. 15 regular close after a partial recovery; not an upper bound |
| Base/adverse reward-to-risk | 0:1 | The base is adverse to the short and the bottom stress is materially worse |
Weights are 20% / 45% / 35% for top/base/bottom. They are subjective, low-confidence path judgments, not observed frequencies: the after-hours move is large enough to make another same-sized gap a minority stress; a revisit to the old 52-week low is a plausible stabilization case; and a partial or full event-gap retracement remains material because regular-session acceptance is absent and the issuer is challenging the rating. These assumptions are not a valuation model.
Probability-weighted reference price: 0.20 × $5.20 + 0.45 × $7.37 + 0.35 × $10.37 = $7.986. That implies -18.7% gross price-only short value from $6.73 before borrow, spread, fees, slippage or distribution obligations. A 30% / 45% / 25% sensitivity yields $7.469, or -11.0% gross short value before costs. The sign remains adverse to a short in both cases.
Current market level and timestamp: $6.73, StockAnalysis after-hours observation, Oct. 8, 2026, 7:59 p.m. EDT; last regular close $8.71 at 4:00 p.m. EDT.
Primary instrument: None. ALHC common stock is only a research reference.
10/5 favorable base move: The highest-probability path is +9.5% in the underlying from the after-hours mark, adverse to a short; no 10% base decline is supported.
10/5 credible adverse move: +54.1% to the Sep. 15 close stress; this is not a ceiling.
10/5 measurement basis: Reference-only after-hours quote; no executable entry.
10/5 status: Reject.
Confidence: Low for the price-path probabilities and company-specific earnings effect; high for the published ratings, issuer statements and cited market observations.
What Should Surprise the Reader
An overall star rating is not a direct measure of each plan’s current dollar margin. CMS’s rating measures quality and member experience across contract-level measures. For Alignment, the 2027 rating is a new input into future quality-bonus eligibility, while the actual economic pass-through depends on contract enrollment, county benchmarks, bids, risk mix, plan design, retention, medical costs and any remedy. Those figures are not present in the Oct. 8 issuer release.
The issuer’s own Q2 baseline also matters. For the quarter ended June 30, ALHC reported $1.336 billion revenue, $182.9 million adjusted gross profit, an 86.3% adjusted medical-benefits ratio, $68.1 million adjusted EBITDA and $36.6 million net income. Health-plan membership was 294,100, up 31.5% year over year. Those are positive operating facts, but they predate the rating release and do not quantify the 2028 bonus loss.
CMS’s 2027 table shows H3815 at 3.5 overall, versus 4.0 in the prior CMS summary-rating table. The issuer says six of seven eligible contracts remained at 4.0 or higher. The rating cut is therefore important but concentrated, not a blanket downgrade of every Alignment contract. Alignment's Oct. 8 SEC filing reports that H3815 serves about 75% of current membership.
The Setup
Alignment operates Medicare Advantage plans under multiple CMS contracts. A plan contract generally must reach 4.0 stars for the quality-bonus threshold described by CMS and the issuer. The new 3.5-star rating on California H3815 removes that contract from the 4.0+ category for the 2027 rating year. CMS states these ratings affect 2028 MA quality-bonus payments.
The market’s short interpretation is that loss of the threshold on a contract serving about 75% of members impairs future earnings, while the 22.73% arithmetic after-hours decline may still understate lower bonus revenue and enrollment damage. The issuer attributes the rating decline primarily to higher industry cut points and weaker performance on some triple-weighted Health Outcomes Survey and Part D measures. It also says CMS retroactively removed bonus calculations linked to the former Excellent Health Outcomes for All Index after the performance period, reducing the value of investments made to align with that methodology. Those are issuer explanations, not an independent finding that care quality is unchanged. The counterparty interpretation is that six other eligible contracts scored at least four stars, no revenue effect is expected in 2026-27, provider risk-sharing and other mitigation should offset part of 2028, management disputes the methodology, and the company cites embedded earnings growth among newer members. Neither side has a quantified 2028 per-share bridge in the sources reviewed.
The Market Price
StockAnalysis reports an Oct. 8 regular close of $8.71, up 1.87% on 9,530,292 shares, with an $8.37-$8.77 session range. The market page later showed an after-hours mark of $6.73 at 7:59 p.m. EDT, down 22.73% by arithmetic from the displayed close; the vendor panel displayed -22.79%. The vendor’s day-session history is sourced to S&P Global Market Intelligence; real-time/after-hours prices are secondary market data. AH trading is thinner and cannot establish an executable short entry or regular-market price discovery.
The same overview page lists 207.44 million shares and a $1.81 billion market capitalization. Holding that vendor share count constant, $6.73 implies about $1.40 billion of equity value; this simple price-derived figure is not a diluted-share reconciliation or valuation model and is not used in the scenario map.
The after-hours print was below the cited pre-event 52-week low of $7.37. That is a descriptive observation, not proof of overreaction. The latest 52-week high shown by the same provider was $25.12. It illustrates how wide the prior price range has been; it is not a future target or ceiling.
The Mispricing
The specific disagreement is whether the 3.5-star H3815 result creates a durable earnings impairment large enough to justify the after-hours repricing, or whether the stock’s 22.79% gap discounts more than the undisclosed 2028 bonus loss. The current close prices neither side clearly because the after-hours price is not a completed regular-session quote and no company earnings bridge isolates the bonus effect.
Price: the latest AH mark is already below the previous 52-week low. Reality: the rating threshold is real and H3815 serves about 75% of members, but six of seven other eligible contracts are 4.0+; the issuer expects no 2026-27 revenue effect and partial 2028 risk-sharing offsets. Catalyst: open enrollment and any formal challenge can change member behavior or the rating state. Positioning: current borrow, short interest, options and forced flows were not verified. The strongest short thesis is plausible, but the article cannot show another 10% base decline from the after-hours reference with no more than 5% adverse move.
The Positioning
No current FINRA short-interest settlement, lending utilization, borrow fee, recall terms, options positioning or identifiable forced flow was verified for this event. The 9.53 million regular-session shares are a volume observation, not proof of short covering or accumulation. The after-hours gap may attract momentum sellers, but it can also create an immediate squeeze if the next regular session reclaims the prior low or the pre-event close. Positioning evidence is therefore unknown, not bearish.
The Catalyst
| Step | State at publication | Test | What it changes |
|---|---|---|---|
| CMS 2027 rating release | Published Oct. 8; CMS table shows H3815 at 3.5 and the prior-year table at 4.0 | Verify the final contract table and any CMS correction or formal remedy | Determines whether the threshold state changes; earnings amount remains unquantified |
| First regular session after release | Pending; current evidence is after-hours only | Compare regular open, close, volume and recovery versus $7.37 and $8.71 | Establishes price acceptance; does not by itself quantify fair value |
| Annual enrollment | Opens Oct. 15 and runs to Dec. 7, 2026 | Track H3815 retention, new enrollment, plan exits and mix when reported | Tests demand response, but open-enrollment intent is not collected premium or profit |
| 2028 quality-bonus payment | CMS says the 2027 star ratings affect 2028 bonus payments; issuer expects provider risk-sharing to offset part of the impact | Reconcile county benchmarks, incremental payments, bids, mitigation and medical costs | Converts the rating state into reported dollars; currently not quantifiable |
| Administrative or court challenge | Issuer says it intends available administrative remedies and litigation; outcome and timing unknown | Verify filings, CMS actions and relief actually granted | Could change the rating or prolong uncertainty; intent is not a ruling |
Cheapest falsification test: Before considering a short, obtain the September 2026 H3815 membership share and a company reconciliation of 2028 bonus dollars under 3.5 versus 4.0 stars, then observe at least one full regular session after the event. A rapid return above $8.71 would disconfirm continuation of the after-hours gap; it would not erase the future payment question.
The Payoff
No trade is proposed. The price-path map uses the AH quote as the current reference only. It compares a second gap of the same percentage size with a retest of the prior 52-week low and a recovery to the Sep. 15 close. These levels are stresses selected from observable prices or a transparent mechanical rule; they are not a valuation model or an upper bound. The after-hours range and current borrow/recall state were not available, so the adverse stress may understate a squeeze. Even with this explicit and intentionally low-confidence map, the highest-probability case is adverse to the short and probability-weighted gross short value is negative before costs.
Price Target and Probability Map
| Scenario | Probability | Target / Level | Return / Payoff from $6.73 | Horizon | Conditions | Evidence Quality |
|---|---|---|---|---|---|---|
| Top Case | 20% | $5.20 | -22.7% underlying; favorable to short | Through Nov. 6, 2026 | A second decline equal in percentage terms to the calculated 22.73% close-to-after-hours gap | Low; mechanical stress only |
| Base Case | 45% | $7.37 | +9.5% underlying; adverse to short | Through Nov. 6, 2026 | Price revisits the pre-event 52-week low as the market waits for member and bonus data | Low; historical level, not a floor |
| Bottom Case | 35% | $10.37 | +54.1% underlying; adverse to short | Through Nov. 6, 2026 | A retest of the Sep. 15 regular close after a partial recovery from recent volatility | Low; prior price stress, not an upper bound |
| Invalidation | n/a | Rebuild from current regular-session quotes and official CMS/company updates | n/a | Any time | The rating is revised, H3815 remains 4.0+ after a remedy, or regular prices recover through the pre-event close while bonus impact remains unquantified | Medium that these are decisive; outcome unknown |
Probability-weighted reference price: 0.20 × $5.20 + 0.45 × $7.37 + 0.35 × $10.37 = $7.986, implying approximately -18.7% gross price-only short value before costs. A 30% / 45% / 25% sensitivity yields $7.469, or approximately -11.0% gross short value before costs. Both weighted prices are above the $6.73 after-hours reference.
Current market level and timestamp: $6.73, StockAnalysis after-hours mark at 7:59 p.m. EDT, Oct. 8, 2026; $8.71 regular close at 4:00 p.m. EDT.
Primary instrument: None. ALHC common stock is a research reference only.
10/5 favorable base move: The highest-probability modeled case is +9.5% in the underlying, adverse to a short; no 10% base decline is supported.
10/5 credible adverse move: +54.1% to the Sep. 15 close stress; further upside is possible.
10/5 measurement basis: Reference-only after-hours observation; no verified entry.
10/5 status: Reject.
Confidence: Low on scenario probabilities, valuation and future bonus impact; high on CMS’s published rating, issuer’s Oct. 8 statements and the cited vendor price observations.
The Kill Shot
The strongest counterparty view is that the headline oversimplifies what happened. Alignment reported 4+ ratings on six of seven other eligible contracts, including three at 4.5 stars. The current 8-K says H3815 serves about 75% of members, but also says 2026-27 revenue is unaffected and provider risk-sharing should offset a portion of the 2028 payment impact. About half of members joined in the last two years, and the issuer expects embedded earnings growth in that cohort to support margins. Q2 revenue rose 31.6%, adjusted EBITDA rose 48.4%, and management raised the midpoint of all full-year guidance metrics. The issuer plans to challenge the methodology. The market has already marked the stock down 22.73% by arithmetic (22.79% per StockAnalysis) after hours before the next full session.
The load-bearing short assumption is that a 3.5 rating on a contract serving about 75% of members removes enough 2028 bonus profit to justify materially lower equity value after risk-sharing and other mitigation. The exact payment loss, enrollment elasticity, contract member count and offset from other contracts remain unknown. A sharp squeeze or corrective rating decision can produce a loss even if some bonus dollars are ultimately lost.
What Could Go Wrong
- The 22.73% calculated after-hours fall may be an overreaction to a rating impact that does not begin until 2028.
- Six other eligible Alignment contracts earned at least four stars; consolidated bonus economics may be better than the single H3815 headline suggests.
- The issuer says H3815 serves approximately 75% of current membership, but does not state the exact contract member count or quantify the net bonus loss after provider risk-sharing and other mitigation.
- Alignment says the downgrade is not expected to affect fiscal 2026 or 2027 revenue and expects risk-sharing to offset part of the 2028 bonus impact; these are issuer expectations, not independently verified outcomes.
- A formal challenge, CMS correction or court relief could change the rating. The issuer’s intent to litigate is not evidence of likely relief, but creates upside event risk.
- Open enrollment could preserve or grow H3815 members despite its 3.5 rating, or members could leave. Neither outcome is yet observed.
- The business has recent growth and positive Q2 net income; the thesis is about future quality-bonus economics, not a proved solvency or revenue crisis.
- Current locate, borrow cost, recall terms, spread, depth, venue quality and exit liquidity are unknown. A small-cap gap can widen or reverse before an order can be closed.
- Price gaps, halts, market-wide moves and after-hours liquidity can exceed the modeled stresses. The $8.71 prior close is not a ceiling.
What Would Prove This Wrong
The short premise should be retired if CMS restores H3815 to at least four stars, if published contract data show the affected membership is now small, or if the company reports that 2028 bonus exposure is substantially offset by other contracts, pricing, benefit design or cost actions. A full-session reclaim of $8.71 would disprove a simple continuation-of-gap path, though it would not by itself prove the bonus economics are immaterial.
Risk Audit
Fundamental: The rating is not a direct EPS delta. Bonus payments depend on enrollment, county benchmarks and contract economics; no company sensitivity is available.
Event: The issuer may challenge the rating. A successful remedy, member resilience or multiple 4.5-star contracts could reverse the narrative.
Market: Current after-hours pricing is reference-only. Postmarket gap and next-session price acceptance are not a fair-value estimate.
Execution: No current locate, borrow, spread, order-book depth, venue, volume-quality or exit-capacity evidence was verified. No short entry is available to this screen.
Best Trade Strategy
No trade. Keep entry.price null and execution blocked. Do not short because the 3.5-star result crossed a threshold: the expected 2028 dollar impact is unquantified, the event price is after hours, the most-probable modeled move is adverse, and a regular-session rebound can be large. Reassess after Oct. 9 price acceptance and obtain an issuer/CMS contract-level earnings bridge before reconsidering the thesis. No options, leverage, margin, market orders, price-floor logic or shorting without verified locate and borrow.
Sources
| Source | Date / timestamp | Use |
|---|---|---|
| CMS 2027 Part C and D performance data and 2027 star-rating data tables ZIP | Published Oct. 8, 2026 | H3815 2027 overall rating of 3.5; CMS source table, not company commentary |
| CMS 2026 star-rating data tables | July 22, 2026 updated table | Prior H3815 4.0 rating and HUM H5216 3.5 comparison |
| CMS 2027 Star Ratings fact sheet | Oct. 8, 2026 | Ratings affect 2028 quality-bonus payments; methodology and industry distribution |
| Alignment Oct. 8 Form 8-K | Filed Oct. 8, 2026 | H3815 serves about 75% of members; no 2026-27 revenue effect expected; 2028 bonus impact, risk-sharing offset, stated causes and mitigation |
| Alignment Oct. 8 rating release | Oct. 8, 2026 | Six of seven eligible contracts at 4+; H3815 at 3.5; issuer says it will pursue administrative remedies and litigation |
| Alignment Q2 2026 Form 10-Q and Q2 results release | Filed July 30, 2026 | June membership 294,100, Q2 revenue, adjusted gross profit, MBR, EBITDA, net income and guidance context |
| ALHC Oct. 8 regular and after-hours price observations | Regular close 4:00 p.m.; AH 7:59 p.m. EDT | $8.71 regular close, $6.73 after-hours reference, and vendor context |
| ALHC historical prices | Oct. 8, 2026 | Regular-session range and 9.53M-share day volume; S&P Global Market Intelligence data displayed by StockAnalysis |
| Aetna 2027 Star Ratings issuer release | Oct. 8, 2026 | More than 69% of MA members in 4+ star 2027 plans |
| CVS Oct. 8 regular and after-hours observations | 7:59 p.m. EDT | $87.80 close and $85.13 after-hours mark; market comparator |
| Humana Oct. 8 price history | 7:59 p.m. EDT | $387.12 regular close and $436.99 after-hours mark; squeeze-risk comparator |
| SPY historical prices | Oct. 8, 2026 | Broad market control |
Research Quality Scorecard
| Criterion | Score | Basis |
|---|---|---|
| Market disagreement | 4/5 | H3815 crossed below 4 stars while ALHC fell 22.73% by displayed-price arithmetic after hours; dollar impact is not disclosed |
| Evidence base | 4/5 | Current official CMS tables, issuer 8-K, Q2 filing and separated regular/AH prices; current SI and net bonus dollars remain unknown |
| Positioning and flows | 2/5 | No current short interest, borrow, utilization, options or forced-flow data verified |
| Catalyst path | 4/5 | First regular session, open enrollment and 2028 bonus mechanism are observable; legal timeline is unknown |
| Payoff architecture | 2/5 | Base path is adverse to the short, expected gross value is negative, and adverse stress exceeds 5% |
| Invalidation discipline | 4/5 | CMS remedy, current contract enrollment and regular-session price acceptance can be checked |
| Differentiated insight | 4/5 | Separates rating threshold, contract concentration, payment year, issuer-wide contract mix and after-hours repricing |
| Client value | 4/5 | Shows why a real downgrade and sharp AH gap still do not make a bounded short |
| Total | 28/40 | Reject / no trade; failed 10/5 economics control classification |
Bottom Line
The H3815 rating fell from 4.0 for 2026 to 3.5 for 2027, and that can affect 2028 quality-bonus payments. It serves about 75% of members, but the exact dollar impact is unknown, Alignment says risk-sharing offsets a portion, six other eligible contracts reached 4.0 or better, and the issuer intends to challenge the result. After the AH mark had already fallen 22.73% by displayed-price arithmetic, the evidence does not support another 10% base decline with adverse upside bounded to 5%. Reject; no trade.
AI Illustration Prompt: Create an institutional financial-editorial illustration for The Mispricing Desk. Show a Medicare Advantage contract ledger with H3815 moving from “4.0” to “3.5” stars, an amber threshold line at 4.0, and a small “2028 QUALITY BONUS” cash bridge whose dollar field is marked “NOT DISCLOSED.” Beside it, show six smaller contract tiles at 4.0+ and one California tile below the threshold. Add a two-price market strip: “ALHC $8.71 REGULAR CLOSE” and “$6.73 AFTER-HOURS / -22.73% CALCULATED.” Make clear the after-hours print is not a regular-session price and the issuer plans to challenge the rating. Use restrained navy, paper white and amber, with no medical imagery and a subtle readable “The Mispricing Desk” watermark.